Screener
Insulet PODD Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenue by Product | ||||||
| Drug Delivery | $5.8M-43.1% | $3.3M-77.9% | $1.9M-83.9% | $7.1M-31.1% | $10.2M+25.9% | |
| International | $251.8M+35.5% | $242.9M+59.5% | $214.1M+50.8% | $202.1M+46.6% | $185.8M+44.9% | |
| U.S.Omnipod | $544.1M+20.1% | $515.6M+28.4% | $567.8M+28.0% | $497.1M+25.7% | $453.2M+28.6% | |
| Property, plant and equipment, net by Geography | ||||||
| Malaysia | $234.1M+45.5% | $224.7M+42.4% | $220M+38.3% | $164.2M— | $160.9M— | |
| Other | $154.2M+738% | $136.4M+910% | $126.9M+1,208% | $23.2M— | $18.4M— | |
| U.S. | $470.3M+0.9% | $469.3M-0.4% | $472.5M-0.7% | $461.9M— | $465.9M— |
FAQ
- How does Insulet break its business down?
- Insulet (PODD) reports total revenue by product across 3 parts — Drug Delivery, International and U.S.Omnipod. Each is extracted from the segment footnotes and tracked over time.
- Where does Insulet's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Insulet's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
